跳至主導覽 跳至搜尋 跳過主要內容

Activity of roniciclib in medullary thyroid cancer

  • Shu Fu Lin*
  • , Jen Der Lin
  • , Chuen Hsueh
  • , Ting Chao Chou
  • , Richard J. Wong
  • *此作品的通信作者
  • Chang Gung University
  • Memorial Sloan-Kettering Cancer Center
  • PD Science, Inc.

研究成果: 期刊稿件 › 文章 › 同行評審

20 引文 斯高帕斯(Scopus)

摘要

Altered cyclin-dependent kinase activity is observed in many human malignancies. Cyclin-dependent kinases that promote cell cycle progression may be promising targets in the treatment of cancer. The therapeutic effects of roniciclib, a cyclindependent kinase inhibitor for medullary thyroid cancer were investigated in the present study. Roniciclib inhibited medullary thyroid cancer cell proliferation in a dose-dependent manner. Roniciclib induced caspase-3 activity and contributed to apoptosis. Cell cycle progression was arrested in the G2 phase. In vivo, roniciclib treatment retarded the growth of tumors of medullary thyroid cancer xenografts. In addition, roniciclib in combination with sorafenib was more effective than either single treatment in a xenograft model. No morbidity was observed in animals treated with single roniciclib therapy and combination treatment of roniciclib and sorafenib. These data provide a rationale for clinical assessment of using roniciclib in the treatment of patients with medullary thyroid cancer.

原文英語
頁(從 - 到)28030-28041
頁數12
期刊Oncotarget
卷9
發行號46
DOIs
出版狀態已出版 - 15 06 2018

文獻附註

Publisher Copyright:
©Lin et al.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Activity of roniciclib in medullary thyroid cancer」主題。共同形成了獨特的指紋。

引用此